IPQ’s approach has evolved from more than 40 years of experience in academic research, governmental research and industrial experience in pharmaceutical, diagnostic and information technology companies, ranging from R&D, drug discovery to strategic planning and mergers/acquisition. This experience includes the initial use of the term “bioinformatics” for molecular processes, the first use of dynamical engineering approaches to model molecular systems in disease, early research into the use of genomic markers in breast cancer (her2/neu), and development of one of the first translational data warehouse systems linking molecular and clinical data (and that has now been commercialized).
MICHAEL N. LIEBMAN, PhD, is a leading scientist and thought leader in the field of biomedical informatics with many years of academic and corporate experience. He serves on 14 scientific advisory boards, including the PhRMA Foundation and is on the Board of Directors of the Nathaniel Adamczyk Foundation for Pediatric ARDS. Michael has been the Managing Director of Strategic Medicine, Inc after serving as the Executive Director of the Windber Research Institute since November, 2003. Previously, he was Director, Computational Biology and Biomedical Informatics at the University of Pennsylvania Cancer Center since September, 2000. He served as Global Head of Computational Genomics at Roche Pharmaceuticals and Director, Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals, Director of Genomics for Vysis, Inc. He was a co-founder of Prosanos, Inc (2000), which became part of United BioSource Corporation in 2011. He was on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Biophysics. He is an Invited Professor at the Shanghai Center for Bioinformatics Technology. Michael is Chair of the Informatics Program of the PhRMA Foundation and also Chair of its new program in Translational Medicine and Therapeutics and is a member of the PhRMA Scientific Advisory Board. He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics. His research focuses on computational models of disease progression stressing risk detection, disease process and pathway modeling and analysis of lifestyle interactions and causal biomarker discovery and focuses on moving bedside problems into the research laboratory to improve patient care and their quality of life. He received a PhD in physical chemistry and protein crystallography from Michigan State University in 1977.